The Wender Group addresses unsolved problems in chemistry, synthesis, biology, medicine, and materials science using new computational tools, new reactions, reagents, strategies and design. Leveraging affiliations with the Medical School, Imaging Center, Chemical Biology Program and Molecular Therapeutics Program as well as numerous internal and external collaborations, the lab emphasizes the use of chemistry, design and synthesis to address problems of significance in biology and medicine, including eradication of HIV/AIDS, overcoming resistant cancer, cancer immunotherapy and treating cognitive disorders such as Alzheimer's disease.
Paul Wender received his B.S. degree from Wilkes University and his Ph.D. in chemistry from Yale University. He was an NIH Postdoctoral Fellow at Columbia University. He served on the faculty at Harvard University and joined the faculty at Stanford University where he is the Francis W. Bergstrom Professor of Chemistry and holds a courtesy appointment in the Department of Chemical and Systems Biology. Professor Wender’s research has been recognized with numerous awards including recently the Tetrahedron Prize, Prelog Medal (Swiss Federal Institute of Technology), Arthur Cope Award (American Chemical Society), Cohen Award for Excellence in Medicinal Chemistry (Israel Chemical Society), and Research Award of the German Bioactives and Biotechnology Leibniz Allaince. He has also been recognized with several teaching awards including the Hoagland Prize, Bing Teaching Award, and the Dean's Teaching Award. He is an elected member of the US National Academy of Sciences, a foreign member of the Royal Spanish Academy of Sciences, and a fellow of the American Association for the Advancement of Science and the American Academy of Arts and Sciences.
McKinlay, C. J., Waymouth, R. M., & Wender, P. A. (2016). Cell-Penetrating, Guanidinium-Rich Oligophosphoesters: Effective and Versatile Molecular Transporters for Drug and Probe Delivery. Journal of the American Chemical Society, 138(10), 3510–3517.
DeChristopher, B. A., Loy, B. A., Marsden, M. D., Schrier, A. J., Zack, J. A., & Wender, P. A. (2012). Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. NATURE CHEMISTRY, 4(9), 705–710.
Stanzl, E. G., Trantow, B. M., Vargas, J. R., & Wender, P. A. (2013). Fifteen Years of Cell-Penetrating Guanidinium-Rich Molecular Transporters: Basic Science, Research Tools, and Clinical Applications. ACCOUNTS OF CHEMICAL RESEARCH, 46(12), 2944–2954.
Wender, P. A., Quiroz, R. V., & Stevens, M. C. (2015). Function through Synthesis-Informed Design. ACCOUNTS OF CHEMICAL RESEARCH, 48(3), 752–760.
Beans, E. J., Fournogerakis, D., Gauntlett, C., Heumann, L. V., Kramer, R., Marsden, M. D., … Wender, P. A. (2013). Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(29), 11698–11703.
Dubikovskaya, E. A., Thorne, S. H., Pillow, T. H., Contag, C. H., & Wender, P. A. (2008). Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 105(34), 12128–12133.
Wender, P. A., Kee, J.-M., & Warrington, J. M. (2008). Practical synthesis of prostratin, DPP, and their analogs, adjuvant leads against latent HIV. SCIENCE, 320(5876), 649–652.
Wender, P. A., Fournogerakis, D. N., Jeffreys, M. S., Quiroz, R. V., Inagaki, F., & Pfaffenbach, M. (2014). Structural complexity through multicomponent cycloaddition cascades enabled by dual-purpose, reactivity regenerating 1,2,3-triene equivalents. NATURE CHEMISTRY, 6(5), 448–452.
Wender, P. A., & Miller, B. L. (2009). Synthesis at the molecular frontier. NATURE, 460(7252), 197–201.
Wender, P. A., & Schrier, A. J. (2011). Total Synthesis of Bryostatin 9. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 133(24), 9228–9231.